| Vol. 6.40 – 4 November, 2022 |
| |
|
|
| Researchers showed that phosphoglycerate dehydrogenase localized to the inner mitochondrial membrane and promoted the translation of mitochondrial DNA-encoded proteins in liver cancer cells. [EMBO Journal] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators found that long-term metformin exposure led to metabolic adaptation of HCC cells, which was characterized by an obvious epithelial-mesenchymal transition phenotype and compensatory elevation of oxidative phosphorylation. [EMBO Molecular Medicine] |
|
|
|
| Scientists reported that sphingosine kinase 2, a key sphingolipid metabolic enzyme, played a critical role in non-alcoholic fatty liver disease-associated HCC. [Oncogenesis] |
|
|
|
| Investigators found that DNASE1L3 was significantly downregulated and served as a favorable prognostic factor in HCC. [Cellular Oncology] |
|
|
|
| By taking advantage of mouse model of high-fat-diet-induced (HFD) obesity and primary mouse hepatocytes as well as human hepatocyte L02 cell line, scientists investigated the involvement of SIRTs during the application of metformin for the therapy of type 2 diabetes. [Clinical Science] |
|
|
|
| The authors constructed a modified-exosome delivery system targeting hepatic stellate cells (HSCs), and constructed the CRISPR/dCas9-SAM system inducing HSCs convert into hepatocyte-like cells in vitro and in vivo. [Nanomedicine] |
|
|
|
|
|
| Scientists review the cellular mechanisms underlying alcohol-induced liver iron loading and discuss how excess iron in patients with alcohol-associated liver disease can promote liver fibrosis and aggravate disease pathology. [American Journal of Pathology] |
|
|
|
|
| Auransa, Inc. announced that the US FDA has accepted its Investigational New Drug (IND) application for AU409, a novel, orally active agent showing anticancer activity in preclinical studies of HCC. [Auransa, Inc. (EIN Presswire)] |
|
|
|
| Omega Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for OTX-2002, the company’s first-in-class epigenomic controller engineered to downregulate c-Myc, for the treatment of HCC. [Omega Therapeutics, Inc.] |
|
|
|
|
| February 5 – 8, 2023 Keystone, Colorado, United States |
|
|
|
|
|
| Aspect Biosystems – Vancouver, British Columbia, Canada |
|
|
|
| Helmholtz Munich – Neuherberg, Germany |
|
|
|
| Novo Nordisk – Seattle, Washington, United States |
|
|
|
| AstraZeneca – Gothenburg, Sweden |
|
|
|
| The Roger Williams Institute of Hepatology – London, England, United Kingdom |
|
|
|
|